AbbVie adds depression indication to Vraylar's label months after Gonzalez touts $4B+ peak sales potential
AbbVie CEO Richard Gonzalez wants to bring Vraylar to new heights. On Friday, regulators set the next phase of his plan in motion.
The FDA approved Vraylar, also known as cariprazine, as an add-on therapy for adults with major depressive disorder (MDD), one of the most common mental disorders in the US. That marks Vraylar’s fourth indication behind schizophrenia, the acute treatment of manic or mixed episodes in those with bipolar I disorder, and depressive episodes in bipolar I patients.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.